FilingReader Intelligence

Boya Bio expands product line, adjusts asset sale strategy

May 31, 2025 at 05:11 AM UTC•By FilingReader AI

Boya Bio-Pharmaceutical Group (SZSE:300294) has received approval for a supplemental application for its intravenous human immunoglobulin (pH4) product, adding a 5g/bottle (10%, 50ml) specification to its existing line. The company noted that Chengdu Rongsheng Pharmaceutical and Guizhou Taibang Biological Products have already received approval for similar products in the Chinese domestic market.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

The company's announcement on obtaining the "Notice of Approval of Supplementary Drug Application"May 30, 2025 at 02:32 AM UTC

Supplementary Source Documents

Announcement on the Company's Joint Investment with Related Parties to Establish a Company and Related TransactionsMay 30, 2025 at 02:34 AM UTC

The company's announcement on adjusting the listing price of 80% equity of Jiangxi Boya Xinhe Pharmaceutical Co., Ltd.May 30, 2025 at 02:33 AM UTC

Boya Bio-Pharmaceutical Group

SZSE:300294•Shenzhen Stock Exchange

Pharmaceuticals

RSS feed for Boya Bio-Pharmaceutical Group

News Alerts

Get instant email alerts when Boya Bio-Pharmaceutical Group publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →